WASHINGTON — The Food and Drug Administration has proposed the first comprehensive update to infant-formula nutrient requirements since 1998, in a rule published on 29 October 2026 that would change specifications for four nutrients, reaffirm four others, and leave the overall list of required nutrients unchanged. The proposal, Phase 1 of a wider review under the agency’s Operation Stork Speed initiative, would increase the minimum levels for iodine and vitamin D, narrow the range for vitamin A, and set a first-ever upper limit for manganese. It is a proposal, not a final rule, and it is not a safety recall: FDA stressed that the changes are not driven by safety concerns and that formulas now on the market remain safe. Parents do not need to switch products because of this proposal.
That reassurance, repeated by FDA and in coverage of the proposal, is the first thing families should take from the story. Regulatory proposals often generate headlines that sound like warnings — “FDA changes formula rules” can be read as “current formula is unsafe” — but in this case the agency’s own framing is the opposite: current formulas meet current requirements, and the proposed changes reflect updated science about infant nutritional needs, not a discovery that existing products are harmful. The proposal’s practical effect, if finalised, would be felt by manufacturers over a period of years, not by parents at the next shop.
FDA Infant Formula Nutrient Proposal: What Would Change
Of the 30 nutrients required in infant formula, eight were assessed in Phase 1. Four would change, four would stay the same, and no nutrient would be added or removed. The four that would change are iodine, vitamin D, vitamin A and manganese, each for a different reason, and each with specific numbers that deserve to be reported accurately rather than summarised loosely as “more” or “less.”
Iodine’s minimum would triple, from 5 to 15 micrograms per 100 kilocalories, while its maximum would fall, from 75 to 50 micrograms per 100 kilocalories. In other words, the proposed iodine range would both rise at the bottom and narrow at the top — ensuring a higher floor for a nutrient important for thyroid function and brain development, while capping the ceiling more tightly. Vitamin D’s minimum would double, from 1 to 2 micrograms per 100 kilocalories (40 to 80 international units), and its maximum would rise from 2.5 to 3 micrograms (100 to 120 IU). Vitamin A, by contrast, would narrow: from 75–225 micrograms retinol activity equivalents per 100 kilocalories to 70–120, with only preformed vitamin A counted and beta-carotene no longer counted toward the total. Manganese, which currently has a minimum of 5 micrograms per 100 kilocalories and no maximum, would gain a proposed range of 1–50 micrograms per 100 kilocalories, including a first-ever upper limit.
Units also change in the proposal, in a way that may confuse readers who compare old and new labels. For vitamins A and D, the proposal moves from international units to metric units, reflecting current scientific practice. A label that looks numerically different may therefore reflect a unit change as well as a substantive change, and parents comparing labels should not assume that a different number, on its own, means a dramatically different product. The substantive changes are those described above, in metric terms, and they are the ones manufacturers would need to meet if the rule is finalised.
The Four Nutrients Assessed and Left Unchanged
The four nutrients assessed and left unchanged — chloride, potassium, selenium and sodium — are as informative as the four that would change. Their inclusion shows that Phase 1 was a review, not a predetermined increase or decrease across the board: the agency examined the evidence for each nutrient and, for these four, concluded that current specifications remain appropriate. That restraint matters for credibility. A review that changed everything would look like a reform for its own sake; a review that changes some specifications and reaffirms others looks like an evidence-based assessment, even to readers who disagree with individual decisions.
For manufacturers, the distinction between changed and unchanged nutrients also matters practically. Reformulating a formula to meet new iodine, vitamin D, vitamin A and manganese specifications is a technical task involving ingredient sourcing, stability testing and labelling, but it does not require rethinking the entire product. For regulators, reaffirming four nutrients provides a baseline against which future phases can be judged. FDA plans two further phases of review, followed by a single final rule covering all phases, rather than a series of separate final rules. That staged approach is designed to give manufacturers and the public a coherent set of requirements, rather than a drip-feed of changes.
Why Vitamin D Is the Most Consequential Change, According to Experts
Among the proposed changes, the vitamin D increase has drawn the most expert attention. Dr. Steven Abrams, of the University of Texas at Austin Dell Medical School, told reporters via Scripps and MedicalDaily coverage that the vitamin D increase is the most consequential change in the proposal. That assessment is expert opinion, attributed to Dr. Abrams, not an FDA finding, and it should be read as such. Its rationale is straightforward: vitamin D is important for bone health and other functions in infancy, and many infants — particularly those who are breastfed, have darker skin, or live in northern latitudes — may receive less vitamin D from sunlight and diet than recommended. Raising the minimum in formula would increase the baseline intake for formula-fed infants, without requiring parents to change feeding practices.
That rationale also illustrates why a regulatory story should not be turned into personal feeding advice. This article does not advise any parent which formula to buy, how much vitamin D any individual infant needs, or whether to supplement. Those are decisions for a paediatrician who knows the child’s history, feeding pattern and health. The proposal’s role is to set the nutritional floor and ceiling for products on the market, not to prescribe an individual child’s diet. A general line — talk to your paediatrician if you have questions about your baby’s formula — is appropriate; specific dosage advice is not, and this article gives none.
Operation Stork Speed and the Timeline to a Final Rule
The proposal sits within Operation Stork Speed, an FDA initiative launched last year to modernise infant-formula regulation. That initiative also increased testing for heavy metals and contaminants and encouraged new products, following recalls and infant-botulism cases that shook confidence in the formula supply. The nutrient proposal should not be linked to any specific recall, however: FDA has not presented it as a response to a particular product failure, and linking it to a recall without evidence would mislead readers about both the proposal and the recall.
The timeline from proposal to final rule is deliberately long, and it is worth stating in full because it tempers any sense of immediate change. Comments will be accepted for 120 days after the proposal’s publication in the Federal Register, under docket FDA-2026-N-10832. FDA plans two further phases of review, then a single final rule, which would take effect 60 days after its publication, with a proposed three-year compliance window for manufacturers to reformulate and relabel. In practice, that means families are unlikely to see reformulated products on shelves for years, and any product bought today will remain compliant with current rules for a long time. The three-year window also reflects the practical difficulty of reformulation: changing a nutrient specification is not a matter of editing a label, but of sourcing ingredients, testing stability and shelf life, and ensuring that the new formulation performs as intended.
Cost is part of that calculation. FDA estimates the proposal would cost manufacturers $8.4 million to $31.7 million per year, with a primary estimate of $17.6 million at a 7% discount rate, according to Reuters reporting. Those figures are agency estimates, not audited industry costs, and they will be tested in public comments from manufacturers, consumer groups and health professionals. Whether costs are passed on to consumers, absorbed by manufacturers, or offset by other efficiencies is not determined by the proposal, and this article does not predict price effects.
What Parents Should — and Should Not — Do Now
The clearest guidance for parents, from FDA and from the coverage reviewed, is to do nothing different. Current formulas remain safe, no switch is needed, and the proposed changes, if finalised, will arrive gradually through reformulated products, not through a sudden withdrawal of existing ones. Parents who are concerned about their baby’s nutrition, vitamin D intake or formula choice should raise those questions with their paediatrician, who can consider the child’s individual circumstances. Parents who rely on the Special Supplemental Nutrition Program for Women, Infants, and Children — WIC — should note that reporting suggested the programme would be unaffected by the proposal, but that line should be verified against FDA’s summary before being relied upon for any individual WIC purchase, and this article does not present it as a guarantee.
For the wider public, the proposal is a reminder of how slowly, and how deliberately, food regulation moves. The last comprehensive review of infant-formula nutrients was in 1998 — before many of today’s parents were themselves parents, and before much of the current science on infant nutrition existed. A review that takes years, proceeds in phases, allows 120 days for comment and three years for compliance may seem glacial, but it reflects the stakes: infant formula is, for many babies, their sole source of nutrition, and a mistake in its composition has consequences that no other food category carries in the same way. That is why FDA’s emphasis — not a safety recall, not an urgent warning, but a science-based update — matters, and why headlines should preserve it.
This FDA action is distinct from the separate 30 October FDA menopause labelling action reported elsewhere in this batch, which concerned hormone-therapy patches for a different population on a different day. Conflating the two would confuse two unrelated regulatory steps that happen to share an agency and a week.
Sources
USN reviewed reporting from multiple outlets for this story. Read more from FDA, Contemporary Pediatrics and MedicalDaily.